UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 6, 2012

ANTHERA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Effective February 6, 2012, the Board of Directors (the “Board”) of Anthera Pharmaceuticals, Inc. a Delaware corporation (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved annual bonuses earned in respect of 2011 performance to be paid partially in the form of Restricted Stock Units, or RSUs, for certain of the Company’s employees, including certain of the Company’s named executive officers.

President and Chief Executive Officer, Paul F. Truex, requested his annual bonus to be paid entirely in RSUs.  The Board granted the request.

Chief Business Officer and Chief Financial Officer, Christopher P. Lowe, requested his annual bonus to be paid entirely in RSUs.  The Board granted the request.

RSUs approved for such named executive officers are as follows:

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3